August 21, 2026 01:45 PM GMT Pharmaron | Asia Pacific M Update Call and NDR Takeaways Key Takeaways CDMO pipeline: By midyear, Pharmaron had 45 PPQs and commercial validations, spanning APIs, intermediates, and formulations. Most programs are at the PPQ stage, with further late-stage conversions expected from 2H26 on. Management highlighted that several pipeline programs address large indications and unmet medical needs, prompting clients to seek scalable and stable capacity ahead of commercialization. With ...